Candidate biomarkers in psychiatric disorders: state of the field

A Abi‐Dargham, SJ Moeller, F Ali… - World …, 2023 - Wiley Online Library
The field of psychiatry is hampered by a lack of robust, reliable and valid biomarkers that can
aid in objectively diagnosing patients and providing individualized treatment …

The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research

SG Potkin, JM Kane, CU Correll, JP Lindenmayer… - NPJ …, 2020 - nature.com
Abstract Treatment-resistant schizophrenia (TRS), the persistence of positive symptoms
despite≥ 2 trials of adequate dose and duration of antipsychotic medication with …

Dopamine and glutamate in schizophrenia: biology, symptoms and treatment

RA McCutcheon, JH Krystal, OD Howes - World Psychiatry, 2020 - Wiley Online Library
Glutamate and dopamine systems play distinct roles in terms of neuronal signalling, yet both
have been proposed to contribute significantly to the pathophysiology of schizophrenia. In …

Economics and mental health: the current scenario

M Knapp, G Wong - World Psychiatry, 2020 - Wiley Online Library
Economics and mental health are intertwined. Apart from the accumulating evidence of the
huge economic impacts of mental ill‐health, and the growing recognition of the effects that …

Neuroimaging biomarkers in schizophrenia

NV Kraguljac, WM McDonald… - American Journal of …, 2021 - Am Psychiatric Assoc
Schizophrenia is a complex neuropsychiatric syndrome with a heterogeneous genetic,
neurobiological, and phenotypic profile. Currently, no objective biological measures—that is …

A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia

CU Correll, O Agid, B Crespo-Facorro… - CNS drugs, 2022 - Springer
Abstract Treatment-resistant schizophrenia (TRS) will affect about one in three patients with
schizophrenia. Clozapine is the only treatment approved for TRS, and patients should be …

Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives

FC Nucifora Jr, E Woznica, BJ Lee, N Cascella… - Neurobiology of …, 2019 - Elsevier
Abstract Treatment resistant schizophrenia (TRS) refers to the significant proportion of
schizophrenia patients who continue to have symptoms and poor outcomes despite …

Heterogeneity and homogeneity of regional brain structure in schizophrenia: a meta-analysis

SP Brugger, OD Howes - JAMA psychiatry, 2017 - jamanetwork.com
Importance Schizophrenia is associated with alterations in mean regional brain volumes.
However, it is not known whether the clinical heterogeneity seen in the disorder is reflected …

Association of age, antipsychotic medication, and symptom severity in schizophrenia with proton magnetic resonance spectroscopy brain glutamate level: a mega …

K Merritt, PK McGuire, A Egerton, A Aleman… - JAMA …, 2021 - jamanetwork.com
Importance Proton magnetic resonance spectroscopy (1H-MRS) studies indicate that altered
brain glutamatergic function may be associated with the pathophysiology of schizophrenia …

Schizophrenia: from neurochemistry to circuits, symptoms and treatments

OD Howes, BR Bukala, K Beck - Nature Reviews Neurology, 2024 - nature.com
Schizophrenia is a leading cause of global disability. Current pharmacotherapy for the
disease predominantly uses one mechanism—dopamine D2 receptor blockade—but often …